IGF2 and cancer: Reports have shown that the CTCF target sites within the H19 ICR are de novo methylated in a wide range of human cancers (14,15), which would lead to prevention of CTCF binding and loss of insulator function at the maternal allele, followed by IGF2 allelic reactivation.